A phase 2/3 trial evaluates the efficacy and safety of neoadjuvant therapy with gemcitabine-oxaliplatin, lenvatinib, and ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology. The article, "The ...

A prospective, multicenter phase 2 trial evaluated the safety of neoadjuvant radiation plus immunotherapy before radical cystectomy for bladder cancer.

A fragmentomic tumor score algorithm for enhanced minimal residual disease detection and prognostic prediction in bile duct cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I ...

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

Phase II study of epacadostat (INCB024360) added to preoperative chemoradiation in patients with locally advanced rectal cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.

China: A neoadjuvant combination regimen comprising chemotherapy, targeted therapy, and immunotherapy has demonstrated significant clinical benefit in patients with resectable ...

The study explores the neoadjuvant approach: administering the immunotherapy drug Keytruda (pembrolizumab) before a surgeon ever picks up a scalpel. Researchers observed dramatic tumor shrinkage and, ...

"Optimal regimens and ideal patients remain undefined," experts say ...

Please provide your email address to receive an email when new articles are posted on . The addition of nivolumab to neoadjuvant chemotherapy significantly increased pathologic complete response among ...